An observational study in Actinic Keratoses, sponsored by MEDA Pharma GmbH & Co. KG. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-07.
Sponsored by MEDA Pharma GmbH & Co. KG (part of Viatris Inc.) · Observational
The purpose of the study is to obtain recurrence rates and long-term safety data for patients who had been treating actinic keratoses on the face and scalp with 5 % Imiquimod Cream in a previous study.
369 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.
This study's enrollment of 72 is below the median of 179 across 37 observational studies indexed under Keratosis, Actinic.
Browse Keratosis, Actinic studies →MEDA Pharma GmbH & Co. KG is the lead sponsor of 24 studies on the registry; none are open to participants now.
First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
At least 18 years old. Females of childbearing potential, with a negative urine pregnancy test, must have been willing to use a medically acceptable method of contraception during the treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No investigational treatments were given during this study.
Drug: Imiquimod
No defined treatments were given during this study.
Efficacy
Efficacy was evaluated by counting AK lesions in the previous treatment area. Subjects at the 1-year follow-up visit with recurrence of lesion(s).
Time frame: one year after completion of study 1487-Imiq
Safety
Safety was evaluated by assessing the area of previous treatment for LSRs and skin quality
Time frame: one year after completion of study 1487-Imiq
Adverse Events
AEs considered by investigator to be possibly or probably related to the 1487-Imiq study medication were documented and recorded.
Time frame: one year after completion of study 1487-Imiq
No study locations are listed for this record.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.